Krause W, Krais T
Eur J Clin Pharmacol. 1986;30(1):61-8. doi: 10.1007/BF00614197.
Plasma levels of the prostacyclin analogue, iloprost, were measured by antibody/GC/MS in healthy male volunteers given 1 and 3 ng/kg per min i.v. for 45 min, and 1 microgram/kg p.o. Following i.v. infusion, the steady-state plasma levels of iloprost were strictly dose-dependent (46 +/- 8 pg/ml and 135 +/- 24 pg/ml). The disposition was biphasic with half-lives of 3-4 min and 0.5 h. After oral administration, absorption of the drug was extremely rapid, the maximum plasma level of 251 +/- 32 pg/ml being achieved after 10 +/- 6 min. The bioavailability was 16 +/- 4%. Platelet aggregation induced by 2 microM ADP was reduced by 53% and 68% at the end of the two different infusions, and by 68% 15 min after p.o. administration. The ex-vivo inhibition of platelet aggregation by iloprost was not affected by preceding drug treatment. The cAMP content of platelets was increased by a factor of 2.5 at the end of the infusions and to a lesser extent 15 min after oral dosing. A slight increase in heart rate occurred during the infusion and within 30 min after oral administration; blood pressure was virtually unaffected. Except for transient side-effects (facial flush and headache) no adverse reactions were observed.
采用抗体/气相色谱/质谱法测定了健康男性志愿者静脉注射每分钟1纳克/千克和3纳克/千克,持续45分钟,以及口服1微克/千克后前列环素类似物依洛前列素的血浆水平。静脉输注后,依洛前列素的稳态血浆水平严格呈剂量依赖性(分别为46±8皮克/毫升和135±24皮克/毫升)。其处置呈双相性,半衰期分别为3 - 4分钟和0.5小时。口服给药后,药物吸收极快,在10±6分钟后达到最大血浆水平251±32皮克/毫升。生物利用度为16±4%。在两次不同输注结束时,2微摩尔二磷酸腺苷诱导的血小板聚集分别降低了53%和68%,口服给药后15分钟降低了68%。依洛前列素对血小板聚集的体外抑制作用不受先前药物治疗的影响。输注结束时血小板环磷酸腺苷含量增加了2.5倍,口服给药后15分钟增加幅度较小。输注期间及口服给药后30分钟内心率略有增加;血压几乎未受影响。除了短暂的副作用(面部潮红和头痛)外,未观察到不良反应。